EFEK PEMBERIAN PARICALCITOL TERHADAP KADAR KALSIUM, FOSFAT, HORMON PARATIROID INTACT DAN DICKKOPF-RELATED PROTEIN 1 PADA PASIEN PENYAKIT GINJAL KRONIS STADIUM 5 DENGAN HEMODIALISA

Frenky Hartono, S.Farm., Apt, 051415153031 (2017) EFEK PEMBERIAN PARICALCITOL TERHADAP KADAR KALSIUM, FOSFAT, HORMON PARATIROID INTACT DAN DICKKOPF-RELATED PROTEIN 1 PADA PASIEN PENYAKIT GINJAL KRONIS STADIUM 5 DENGAN HEMODIALISA. Thesis thesis, Universitas Airlangga.

[img]
Preview
Text (abstrak)
abstrak.pdf

Download (262kB) | Preview
[img] Text (full text)
EFEK PEMBERIAN PARICALCITOL TERHADAP KADAR KALSIUM, FOSFAT, HORMON PARATIROID INTACT DAN DICKKOPF.pdf
Restricted to Registered users only until 16 October 2020.

Download (2MB)

Abstract

Mineral and bone disorder is one of complication in hemodialysis (HD) patients. It characterized by metabolic abnormalities of calcium, phosphate, parathyroid hormone (PTH), and vitamin D, abnormality bone turnover, and vascular calcification. Beside that this complication will affect Wnt pathway. The common therapy for this complication was vitamin D compound like paricalcitol. Paricalcitol will take effect on calcium, phosphate, parathyroid hormone, and Dickkopf-related protein 1 (DKK-1), a inhibitor of Wnt pathway. Objectives: To analyze effectiveness of paricalcitol on calcium, phosphate, PTH, and DKK1 in hemodialysis patient with mineral and bone disorder Methods: An observational prospective cohort study comparing the effectiveness of paricalcitol on calcium, phosphate, PTH and DKK-1 in hemodialysis. A total of 9 patients were enrolled at Adi Husada Undaan Wetan Surabaya Hospital and be divided into 4 patients in paricalcitol group, 5 patients in without paricalcitol group. Paricalcitol give in this study were 10μg every week. Level of calcium, phosphate, PTH, and DKK-1 measured before initiation of study and after 3 months treatment Results: The baseline characteristics of the two groups were similar. The change of PTH in paricalcitol group from (616.5 ± 98.5)pg/mL into (671.8 ± 476.0)pg/mL and in without paricalcitol group from (734.7 ± 338.2)pg/mL into (867.0 ± 420.1)pg/mL. There is significant different in without paricalcitol group’s PTH change significantly (p=0.005). Spearman’s rho test show no correlation between PTH and DKK-1 level (p=0.179; r=0.331) Conclusion: According to this study, three months therapy of paricalcitol in HD patients can maintained PTH level and gave no effect on calcium, phosphate, and DKK1. There are no correlation of PTH and DKK-1 in HD patients.

Item Type: Thesis (Thesis)
Additional Information: KKB KK-2 TFK 21/17 Har e
Uncontrolled Keywords: Chronic Kidney Disease, Hemodialysis, Mineral and Bone Disorder, Paricalcitol, Calcium, Phosphate, Parathyroid hormone, DKK-1
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: 05. Fakultas Farmasi > Farmasi Klinis
Creators:
CreatorsNIM/NIDN
Frenky Hartono, S.Farm., Apt, 051415153031UNSPECIFIED
Contributors:
ContributionNameNIDN/NIDK/NUP
ContributorBudi Suprapti, Dr. , M.Si., AptUNSPECIFIED
Depositing User: Unnamed user with email indah.fatma@staf.unair.ac.id
Date Deposited: 15 Oct 2017 21:13
Last Modified: 15 Oct 2017 21:13
URI: http://repository.unair.ac.id/id/eprint/63889
Sosial Share:

Actions (login required)

View Item View Item